Synergistic Effects of Resveratrol and Temozolomide Against Glioblastoma Cells: Underlying Mechanism and Therapeutic Implications
Authors:
- Yusi LiuYLYusi Liu
- Xue SongXSXue Song
- Moli WuMWMoli Wu
- Jiao WuJWJiao Wu
- Jia LiuJLJia Liu
Open Access
- 1 September 2020
- journal article
- research article
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 12, 8341-8354
Abstract
Purpose: Temozolomide (TMZ) is a commonly used anti-glioblastoma (GBM) drug. However, glioblastoma cells frequently show primary and acquired resistance to TMZ. As a promising anti-GBM candidate, resveratrol (Res) faces the similar problem as TMZ. Although resveratrol combined with TMZ (Res/TMZ) has been reported to be used to treat GBMs, it remains unclear whether this combination is broad-spectrum for all glioma cells until now, especially for GBM cells/cases with dual drug resistance. The study aimed to evaluate the synergistic effects of resveratrol and TMZ against GBMs and identify the underlying mechanisms. Materials and Methods: Drug sensitivities of rat RG-2, human LN-18 and LN-428 cell lines and effectiveness of Res/TMZ combinations were investigated via multiple experimental methods. O6-methylguanine-DNA methyltransferase (MGMT) was observed by Western blotting and immunocytochemistry (ICC). Transducer and activator of transcription 3 (STAT3) signaling pathway and expression changes of STAT3-related gene were detected to explore the possible synergistic mechanism. Results: One hundred micromolar resveratrol and 500 μM TMZ inhibited the growth of RG-2 cells and the low-dose combination (25 μM/250 μM) showed similar suppressive effects. LN-18 and, especially, LN-428 cells were neither sensitive to 100 μM resveratrol nor to 500 μM TMZ, while their growth was suppressed by combination of 75 μM Res/750 μM TMZ with the suppressive rates of 62.5% and 28.6% and apoptosis rates of 11.9% and 7.4%, respectively. Resveratrol had regulatory effect on the expression of MGMT and it could significantly down-regulate MGMT overexpression caused by TMZ. In addition, STAT3/Bcl-2/survivin signaling pathway was also remarkably inhibited in Res/TMZ-treated GBM cells. Conclusion: Our results demonstrated synergistic effects of Res/TMZ on RG-2 cells and their bilaterally sensitizing effects to LN-18 and LN-428 cells. Frequent upregulation of MGMT and activation of STAT3 are the unfavorable factors for the treatment of GBMs and they may be the potential targets of Res/TMZ therapy.Keywords
This publication has 35 references indexed in Scilit:
- Resveratrol abrogates the Temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the Temozolomide-induced senescence in glioma cellsBMC Cancer, 2013
- Perillyl Alcohol for the Treatment of Temozolomide-Resistant GliomasMolecular Cancer Therapeutics, 2012
- CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005-2009Neuro-Oncology, 2012
- Overcoming Temozolomide Resistance in Glioblastoma via Dual Inhibition of NAD+ Biosynthesis and Base Excision RepairCancer Research, 2011
- O6-Methylguanine DNA methyltransferase expression in tumor cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with primary glioblastomaBrain Tumor Pathology, 2011
- Phase I Study of Temozolomide and Laromustine (VNP40101M) in Patients With Relapsed or Refractory LeukemiaClinical Lymphoma Myeloma and Leukemia, 2010
- Gene expression profiling predicts response to temozolomide in malignant gliomasInternational Journal of Oncology, 2010
- Therapy for Recurrent High-Grade Gliomas: Does Continuous Dose-Intense Temozolomide Have a Role?Journal of Clinical Oncology, 2010
- O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patientsNeuro-Oncology, 2009
- Temozolomide in Malignant Gliomas of Childhood: A United Kingdom Children’s Cancer Study Group and French Society for Pediatric Oncology Intergroup StudyJournal of Clinical Oncology, 2002